Infection and Drug Resistance (Oct 2020)
Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19
Abstract
Raphael B Stricker, Melissa C Fesler Union Square Medical Associates, San Francisco, CA, USACorrespondence: Raphael B StrickerUnion Square Medical Associates, 450 Sutter Street, Suite 1504, San Francisco, CA 94108, USATel +1 415-399-1035Email [email protected]: To date, more than 35 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent of coronavirus disease 2019 (COVID-19), and more than one million have died in the COVID-19 pandemic. International economies are stalled and social isolation based on palpable fear of death remains the order of the day. The United States and other countries are moving toward resuming work activities and social interaction to boost economic recovery. While this makes financial sense, from a medical perspective our population has already suffered and will continue to suffer severe losses in the absence of a viable aggressive prophylaxis strategy for SARS-CoV-2. Herein, we present a plan to address this problem.Keywords: coronavirus, SARS, COVID-19, prophylaxis
